Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | CTSE | P14091 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3919908 | 0.92 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAMAPTALDH1A1TP53 | |
| SCHEMBL1001879 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAMAPTALDH1A1MEN1 | |
| SCHEMBL3491340 | 0.83 | NAMPT (0.46) | SMN1; SMN2LMNAMAPTTP53MEN1 | |
| SCHEMBL2470592 | 0.80 | TSHR (0.58) | SMN1; SMN2LMNAMAPTALDH1A1TP53 | |
| SCHEMBL1973194 | 0.80 | GAA (0.50) | SMN1; SMN2ALDH1A1MEN1KMT2ACYP2C19 | |
| SCHEMBL2781482 | 0.78 | GPR119 (0.41) | SMN1; SMN2TP53MEN1KMT2ACYP2C19 | |
| SCHEMBL12493302 | 0.78 | MAPT (0.55) | SMN1; SMN2LMNAMAPTALDH1A1TP53 | |
| SCHEMBL13510871 | 0.78 | GAA (0.52) | SMN1; SMN2ALDH1A1MEN1KMT2ACYP2C19 | |
| SCHEMBL28525675 | 0.78 | LMNA (0.55) | SMN1; SMN2LMNAMAPTALDH1A1TP53 | |
| SCHEMBL19033759 | 0.77 | CYP2C19 (0.54) | SMN1; SMN2LMNAALDH1A1TP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| WO-2007125325-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | PKN2, PKN1, CSNK1A1 | SMN1; SMN2 2711/4885LMNA 1963/4885MAPT 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.